Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors

Creative Commons License

Atalar B., Mustafayev T., Sio T., Sahin B., Gungor G., Aydın G., ...Daha Fazla

Radiology and Oncology, cilt.54, sa.4, ss.480-487, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2478/raon-2020-0039
  • Dergi Adı: Radiology and Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.480-487
  • Anahtar Kelimeler: lung cancer, radiation, stereotactic ablative radiotherapy, stereotactic body radiation therapy, survival outcomes, toxicity, BODY RADIATION-THERAPY, CELL LUNG-CANCER, EARLY-STAGE, PHASE-II
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background. Stereotactic ablative radiotherapy (SABR) is effective for thoracic cancer and metastases; however, adverse effects are greater for central tumors. We evaluated factors affecting outcomes and toxicities after SABR for patients with primary lung and oligometastatic tumors.